Galapagos delivers second pre-clinical candidate in alliance with GlaxoSmithKline
Galapagos receives €5.2 million in milestone payments
Galapagos NV announced that it has successfully identified a second pre-clinical candidate compound in its osteoarthritis alliance with GlaxoSmithKline (GSK). Galapagos also reached a milestone on another compound in the alliance. Together these milestones trigger payments totaling €5.2 million to Galapagos.
This pre-clinical candidate is a small molecule that meets all the chemical and biological criteria set by GSK for a potential new medicine. The candidate was developed by Galapagos against a novel target discovered with Galapagos' proprietary platform. The molecule is now ready for scale up chemistry and comprehensive safety evaluation, with the goal of entering Phase I clinical research in 2010.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.